Stock Track | Absci Plunges 16.77% After-Hours on Q3 Revenue Miss and Wider-Than-Expected Losses

Stock Track11-13

Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's performance fell short of analyst expectations, triggering a significant sell-off.

For the third quarter, Absci reported revenue of $378,000, which represents a steep 77.78% decrease compared to the same period last year and falls significantly below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses.

The disappointing results were accompanied by concerning financial metrics. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million. Despite the challenges, the company reported some positive developments, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145586936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145586936","market":"hk","top_or_hot":-1,"title":"Stock Track | Absci Plunges 16.77% After-Hours on Q3 Revenue Miss and Wider-Than-Expected Losses","media":"Stock Track","content":"<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's performance fell short of analyst expectations, triggering a significant sell-off.</p>\n\n<p>For the third quarter, Absci reported revenue of $378,000, which represents a steep 77.78% decrease compared to the same period last year and falls significantly below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses.</p>\n\n<p>The disappointing results were accompanied by concerning financial metrics. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million. Despite the challenges, the company reported some positive developments, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Absci Plunges 16.77% After-Hours on Q3 Revenue Miss and Wider-Than-Expected Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Absci Plunges 16.77% After-Hours on Q3 Revenue Miss and Wider-Than-Expected Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's performance fell short of analyst expectations, triggering a significant sell-off.</p>\n\n<p>For the third quarter, Absci reported revenue of $378,000, which represents a steep 77.78% decrease compared to the same period last year and falls significantly below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses.</p>\n\n<p>The disappointing results were accompanied by concerning financial metrics. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million. Despite the challenges, the company reported some positive developments, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"","article_id":"1145586936","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145586936","pubTimestamp":1762983185,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation."},"translate_title":"个股追踪|Absci盘后暴跌16.77%因Q3营收不及预期亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":1},"content_text":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results. The biotechnology company's performance fell short of analyst expectations, triggering a significant sell-off.\nFor the third quarter, Absci reported revenue of $378,000, which represents a steep 77.78% decrease compared to the same period last year and falls significantly below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses.\nThe disappointing results were accompanied by concerning financial metrics. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million. Despite the challenges, the company reported some positive developments, including interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145586936","isCrawlerRequest":true}